Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease

Arthritis Res Ther. 2019 Feb 13;21(1):54. doi: 10.1186/s13075-019-1843-9.

Giulio Cavalli^{1

2

3}, Alessandro Tomelleri^{4

5}, Giacomo De Luca^{4

5}, Corrado Campochiaro⁴, Charles A Dinarello^{6

7}, Elena Baldissera⁴, Lorenzo Dagna^{4

5}

¹ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy. cavalli.giulio@gmail.com.
² Vita-Salute San Raffaele University, Milan, Italy. cavalli.giulio@gmail.com.
³ Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. cavalli.giulio@gmail.com.
⁴ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy.
⁵ Vita-Salute San Raffaele University, Milan, Italy.
⁶ Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
⁷ Department of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA.

No abstract available

Publication types